Skip to main content

Table 2 Summary RRs and 95% CI

From: Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis

Complications ZOL vs no ZOL Upfront ZOL vs delayed ZOL
  RR (95%CI) P Number of studies RR (95%CI) P Number of studies
Arthralgia 1.162 (1.096-1.232) # 0.466 4 1.022 (0.932-1.120) 0.850 3
Bone pain 1.257 (1.149-1.376) 0.193 2 1.284 (1.135-1.453) 0.460 2
Muscle pain 1.198 (0.901-1.594) 0.366 2 1.071 (0.942-1.217) 0.422 3
  1. RR, risk ratio; CI, confidence interval; ZOL, zoledronic acid;
  2. *P value for between-study heterogeneity; #the number in AZURE trial included the number of arthralgia and muscle pain.